DENIS WILLIAMS: Open Payments
NPI 1962093492 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,721 in 77 payments from 12 companies in 2025. Trend: 2023 $512 · 2024 $892 · 2025 $1,721
Food & beverage: $1,721
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $285 |
| ABBVIE INC. | 16 | $249 |
| Otsuka America Pharmaceutical, Inc. | 11 | $226 |
| Neurocrine BioSciences, Inc. | 9 | $177 |
| E.R. Squibb & Sons, L.L.C. | 3 | $176 |
| Vanda Pharmaceuticals Inc. | 8 | $150 |
| Teva Pharmaceuticals USA, Inc. | 4 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $120 |
| Luye Pharma (USA) Ltd. | 4 | $76 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $70 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, COBENFY, REXULTI, AUSTEDO XR, TRINTELLIX, FANAPT.
Industry payments across NV — which companies pay providers there.
